ArticleBMC infectious diseases2014
Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population.
Article in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Prospective Open-Label Safety Study of Edaravone Dexborneol in Filipino Patients With Acute Ischemic Stroke.Brain and behavior · 2026Article
- Estimated Glomerular Filtration Rate and Associated Factors Prior to Anti-Tuberculosis Initiation Among Tuberculosis Patients at Bale Zone Hospitals Southeast Ethiopia: A Cross-Sectional Study Design.Infection and drug resistance · 2026Article
- Article
- Rifampin-induced Acute Kidney Injury Is Associated With Hemolysis and Drug Re-exposure.Kidney medicine · 2026Article
- Article
- Construction and Validation of a Nomogram-Based Predictive Model for Acute Kidney Injury Caused by Drug Resistance to Tuberculosis.International journal of general medicine · 2025Article
- Article
- Rifampicin-induced acute tubulointerstitial nephritis during pulmonary tuberculosis treatment: A case report.Respirology case reports · 2023Article
- Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature Review.Infectious diseases and therapy · 2023Article
- Inferior vena cava and renal vein thrombosis: a rare cause of acute kidney injury in tuberculosis.BMJ case reports · 2023Article
- Rifampin-induced acute kidney injury and hemolysis: A case report and literature review of a rare condition.Clinical case reports · 2022Article
- A risk prediction model for acute kidney injury in patients with pulmonary tuberculosis during anti-tuberculosis treatment.Renal failure · 2022Article
- Bridging the Gap in End Tuberculosis Targets in the Elderly Population in Eastern China: Observational Study From 2015 to 2020.JMIR public health and surveillance · 2022Observational
- Acute Tubular Necrosis and Thrombocytopenia Associated With Rifampin Use: Case Report and Review.Open forum infectious diseases · 2022Article
- Vitamin D deficiency among apparently healthy children and children with common medical illnesses in Sub-Saharan Africa: A systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2022Review
- Amelioration of Nephrotoxicity in Mice Induced by Antituberculosis Drugs UsingInternational journal of nephrology · 2022Article
- Clinical Characteristics and Outcomes in Chronic Kidney Disease Patients with Tuberculosis in China: A Retrospective Cohort Study.International journal of general medicine · 2022Article
- Article
- Etiopathogenesis, Challenges and Remedies Associated With Female Genital Tuberculosis: Potential Role of Nuclear Receptors.Frontiers in immunology · 2020Review
- Urogenital tuberculosis - epidemiology, pathogenesis and clinical features.Nature reviews. Urology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients on anti-tuberculosis treatment may develop acute kidney injury (AKI), but little is known about the renal outcome and prognostic factors, especially in an aging population. This study aimed to calculate the incidence of AKI due to anti-TB drugs and analyze the outcomes and predictors of renal recovery.
methodsFrom 2006 to 2010, patients on anti-TB treatment were identified and their medical records reviewed. Acute kidney injury was defined according to the criteria established by the AKI Network, while renal recovery was defined as a return of serum creatinine to baseline. Predictors of renal recovery were identified by Cox regression analysis.
resultsNinety-nine out of 1394 (7.1%) patients on anti-TB treatment had AKI. Their median age was 68 years and there was male predominance. Sixty (61%) developed AKI within two months of anti-TB treatment, including 11 (11%) with a prior history of rifampin exposure. Thirty (30%) had co-morbid chronic kidney disease or end-stage renal disease. The median time of renal recovery was 39.6 days (range, 1-180 days). Factors predicting renal recovery were the presence of fever, rash, and gastro-intestinal disturbance at the onset of AKI. Sixty-two of the 71 (87%) patients who recovered from AKI had successful re-introduction or continuation of rifampin.
conclusionsRenal function impairment is not a rare complication during anti-TB treatment in an elderly population. The presence of fever and rash may be associated with renal recovery. Rifampin can still be used in most patients who recover from AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.